GTHX
Price:
$7.16
Market Cap:
$377.75M
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, a (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer; Phase III clinical trial for the treatment of first line triple negative breast cancer; Phase II clinical ...[Read more]
Industry
Biotechnology
IPO Date
2017-05-17
Stock Exchange
NASDAQ
Ticker
GTHX
According to G1 Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is 26.28%. This represents a change of -220.21% compared to the average of -21.86% of the last 4 quarters.
The mean historical ROE of G1 Therapeutics, Inc. over the last ten years is -66.15%. The current 26.28% ROE has changed -139.73% with respect to the historical average. Over the past ten years (40 quarters), GTHX's ROE was at its highest in in the June 2023 quarter at 15.14%. The ROE was at its lowest in in the June 2022 quarter at -63.22%.
Average
-66.15%
Median
-67.75%
Minimum
-214.64%
Maximum
39.78%
Discovering the peaks and valleys of G1 Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 11.53%
Maximum Annual ROE = 39.78%
Minimum Annual Increase = -945.61%
Minimum Annual ROE = -214.64%
Year | ROE | Change |
---|---|---|
2023 | -135.55% | -36.85% |
2022 | -214.64% | -945.61% |
2021 | 25.38% | 11.53% |
2020 | 22.76% | -37.21% |
2019 | 36.24% | -8.88% |
2018 | 39.78% | -161.79% |
2017 | -64.38% | -9.49% |
2016 | -71.13% | -23.73% |
2015 | -93.25% | -54.88% |
The current ROE of G1 Therapeutics, Inc. (GTHX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-108.27%
5-year avg
-53.16%
10-year avg
-66.15%
G1 Therapeutics, Inc.’s ROE is greater than Allogene Therapeutics, Inc. (-58.07%), less than Heron Therapeutics, Inc. (76.79%), greater than Annexon, Inc. (-38.99%), greater than Sangamo Therapeutics, Inc. (-266.47%), greater than X4 Pharmaceuticals, Inc. (-32.51%), greater than HOOKIPA Pharma Inc. (-49.25%), greater than Mereo BioPharma Group plc (-69.11%), less than Galera Therapeutics, Inc. (14.34%), greater than Acumen Pharmaceuticals, Inc. (-32.99%), less than Atara Biotherapeutics, Inc. (965.52%), greater than Fate Therapeutics, Inc. (-45.88%), greater than Sana Biotechnology, Inc. (-94.47%), greater than Caribou Biosciences, Inc. (-45.46%), greater than Arcus Biosciences, Inc. (-45.59%), greater than Day One Biopharmaceuticals, Inc. (-22.40%), greater than Blueprint Medicines Corporation (-47.66%), greater than Axsome Therapeutics, Inc. (-234.35%), greater than PDS Biotechnology Corporation (-139.57%), greater than Amylyx Pharmaceuticals, Inc. (-85.39%), less than Coherus BioSciences, Inc. (0.40%), greater than Larimar Therapeutics, Inc. (-35.87%), less than Puma Biotechnology, Inc. (41.50%), greater than MacroGenics, Inc. (-89.42%),
Company | ROE | Market cap |
---|---|---|
-58.07% | $438.21M | |
76.79% | $240.31M | |
-38.99% | $557.49M | |
-266.47% | $521.62M | |
-32.51% | $98.92M | |
-49.25% | $18.30M | |
-69.11% | $589.54M | |
14.34% | $1.63M | |
-32.99% | $107.54M | |
965.52% | $76.78M | |
-45.88% | $189.06M | |
-94.47% | $390.72M | |
-45.46% | $153.03M | |
-45.59% | $1.46B | |
-22.40% | $1.28B | |
-47.66% | $5.75B | |
-234.35% | $4.22B | |
-139.57% | $61.35M | |
-85.39% | $274.19M | |
0.40% | $169.36M | |
-35.87% | $241.19M | |
41.50% | $148.24M | |
-89.42% | $204.61M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like G1 Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like G1 Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is G1 Therapeutics, Inc.'s ROE?
How is the ROE calculated for G1 Therapeutics, Inc. (GTHX)?
What is the highest ROE for G1 Therapeutics, Inc. (GTHX)?
What is the 3-year average ROE for G1 Therapeutics, Inc. (GTHX)?
What is the 5-year average ROE for G1 Therapeutics, Inc. (GTHX)?
How does the current ROE for G1 Therapeutics, Inc. (GTHX) compare to its historical average?